

# FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * LUCI DAVID P			2. Issuer Name and Ticker or Trading Symbol ACCESS PHARMACEUTICALS INC [accp.ob]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> 10% Owner <input type="checkbox"/> Other (specify below)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 02/04/2008					
(Street)			4. If Amendment, Date Original Filed (Month/Day/Year)			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
(City)	(State)	(Zip)	<b>Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned</b>					

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common stock	12/15/2008		J(1)		173	A	\$ 2.75	173	D	
Common stock	01/05/2009		J(1)		785	A	\$ 0.96	958	D	
Common stock	03/09/2009		J(2)		60,000	A	\$ 1.15 (2)	60,958	D	
Common stock	04/01/2009		J(3)		2,259	A	(3)	63,217	D	
Common stock	06/01/2009		A(4)		200,000 (4)	A	(4)	263,217	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Series A Cumulative Convertible Preferred Stock	\$ 3	02/04/2008		P		2.50		(5)	(5)	Common stock	8,333	\$ 10,000	33,333	D	
Common stock purchase warrants	\$ 3.50	02/04/2008		P		4,167		02/04/2008	02/04/2014	Common stock	4,167	(6)	37,500	D	
Stock option (right to buy)	\$ 2.90	05/21/2008		A		6,000		11/21/2008	05/21/2018	Common stock	6,000	\$ 2.90	43,500	D	
Stock option (right to buy)	\$ 1.38	05/27/2009		A		25,000		05/27/2009 (7)	05/27/2019	Common stock	25,000	\$ 1.38	68,500	D	
Stock option (right to buy)	\$ 1.38	05/27/2009		A		20,000		05/27/2009 (7)	05/27/2019	Common stock	20,000	\$ 1.38	88,500	D	

### Reporting Owners

Reporting Owner: \_\_\_\_\_

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
LUCI DAVID P	X			

## Signatures

David P. Luci (by Stephen B. Thompson)	11/02/2009
<small>Signature of Reporting Person</small>	<small>Date</small>

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Dividend shares on Series A Cumulative Convertible Preferred Stock
- (2) Shares issued per the Release Agreement between Mr. Luci and Access Pharmaceuticals regarding its acquisition of MacroChem Corporation and Mr. Luci's employment agreement with MacroChem Corporation
- (3) Shares issued for exchange of MacroChem shares for Access Pharmaceuticals shares due to Access Pharmaceuticals acquisition of MacroChem Corporation
- (4) Shares granted per consulting agreement. 66,667 vest immediately; 66,666 vest on 01/01/2010; and 66,666 vest on 06/01/2010.
- (5) These securities are exercisable at any time and have no expiration date.
- (6) These warrants were issued as additional consideration for the purchase of the Series A Cumulative Convertible Preferred Stock.
- (7) 50% vest immediately; 50% vest on 11/27/2009.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.